Adjuvant Analgesics

Adjuvant analgesics, also called co-analgesics, are drugs whose primary indication is something other than pain but which relieve pain in certain conditions. The category includes particular antidepressants and anticonvulsants - the mainstays of neuropathic pain treatment - as well as corticosteroids and other agents used to enhance analgesia or treat specific pain mechanisms.

Definition

Adjuvant analgesics are medications developed for non-pain indications - notably certain antidepressants, anticonvulsants, and corticosteroids - that provide analgesia in specific pain conditions, especially neuropathic pain, by modulating neuronal excitability or descending pain control.

Scope

The entry covers the major classes used as adjuvant analgesics - tricyclic and serotonin-noradrenaline reuptake-inhibiting antidepressants, gabapentinoid and other anticonvulsants, and corticosteroids - their distinct mechanisms, and their particular value in neuropathic and mixed pain states where nonopioids and opioids alone are often insufficient. It treats the topic as a pharmacological category and does not give dosing or treatment recommendations.

Core questions

• Why are drugs developed for depression or epilepsy effective against neuropathic pain?
• How do tricyclic antidepressants, SNRIs, and gabapentinoids differ in their analgesic mechanisms?
• What roles do corticosteroids and other adjuvants play in specific pain syndromes?
• Why are adjuvants considered first-line for neuropathic pain rather than nonopioids?

Key concepts

• Co-analgesia
• Neuropathic pain
• Tricyclic antidepressants
• Serotonin-noradrenaline reuptake inhibitors (SNRIs)
• Gabapentinoids and other anticonvulsants
• Descending monoaminergic modulation
• Corticosteroids as adjuvants
• Number needed to treat for neuropathic pain

Mechanisms

Adjuvant analgesics relieve pain by mechanisms unrelated to opioid receptors or cyclooxygenase. Tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors increase synaptic monoamines and strengthen descending inhibitory control of spinal pain transmission, which underlies their efficacy in neuropathic pain. Gabapentinoid anticonvulsants act on voltage-gated calcium channel subunits to reduce excitatory neurotransmitter release from sensitised neurons, and other anticonvulsants stabilise neuronal membranes. Corticosteroids reduce inflammation and oedema through genomic and non-genomic actions and are used as adjuvants in conditions such as nerve compression. Because these agents target the altered signalling of neuropathic pain, they are recommended ahead of nonopioids for that indication, where their effect is often summarised by the number needed to treat.

Clinical relevance

Adjuvant analgesics are central to the rational, mechanism-based treatment of neuropathic and mixed pain and to opioid-sparing strategies; understanding their distinct modes of action supports appraisal of the trial and meta-analytic evidence behind them. This entry describes their pharmacology as a reference and does not offer dosing or individualised treatment advice.

Epidemiology

Neuropathic pain affects a substantial minority of adults and responds poorly to conventional nonopioids, which has made adjuvant antidepressants and anticonvulsants the recommended first-line pharmacotherapy in major reviews and guidelines. Effect sizes are modest and many patients obtain only partial relief, motivating combination and multimodal approaches.

History

The analgesic effect of antidepressants and anticonvulsants was recognised through clinical observation in the mid-twentieth century, well before their mechanisms in pain were understood. Systematic trials and later meta-analyses established their efficacy in neuropathic pain and ranked them ahead of other agents, consolidating the concept of the adjuvant or co-analgesic and placing it at the centre of neuropathic-pain treatment.

Debates

Which adjuvants should be first-line for neuropathic pain?

Meta-analytic evidence supports tricyclic antidepressants, SNRIs, and gabapentinoids as first-line for neuropathic pain, but their modest and variable effect sizes and side-effect profiles keep the optimal sequencing and combination under discussion.

Seminal works

• finnerup-2015

Frequently asked questions

Why are antidepressants used to treat pain?

Certain antidepressants raise levels of serotonin and noradrenaline and strengthen the nervous system's descending inhibition of pain signals, an effect independent of their action on mood, which makes them effective for neuropathic pain.

What is an adjuvant analgesic?

An adjuvant or co-analgesic is a drug whose main approved use is for another condition - such as depression, epilepsy, or inflammation - but which relieves pain in particular situations, most importantly neuropathic pain.